We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$450M
AUM Growth
-$279M
Cap. Flow
-$152M
Cap. Flow %
-33.77%
Top 10 Hldgs %
60.29%
Holding
78
New
9
Increased
12
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$35.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.3M
3
OSUR icon
OraSure Technologies
OSUR
+$12.9M
4
CTLT
CATALENT, INC.
CTLT
+$11.9M
5
AMRX icon
Amneal Pharmaceuticals
AMRX
+$7.57M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$34M
2
AZN icon
AstraZeneca
AZN
+$27.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.9M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.16%
2 Communication Services 1.48%
3 Miscellaneous 1.32%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
76
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-70,594
Closed -$6.82M
ZGNX
77
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-5,500
Closed -$149K
BDSI
78
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-583,504
Closed -$2.54M
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Eversept Partners held 78 positions worth $450M, down 38% from $729M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $152M in Q3 2020, closing 29 positions and reducing 27 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Communication Services and Miscellaneous.

Against the trend, Eversept Partners opened a new position in Teva Pharmaceuticals worth $21.6M.

  • Eversept Partners's largest Q3 2020 buy was Teva Pharmaceuticals: 2,394,355 shares worth $21.6M.
  • Eversept Partners added most to Amarin Corp in Q3 2020, an estimated $35.2M increase.
  • Eversept Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $34M.
  • Eversept Partners fully exited Myovant Sciences Ltd. in Q3 2020, selling an estimated $15.7M.
  • Eversept Partners's ten largest holdings make up 60% of its $450M portfolio in Q3 2020.
  • Eversept Partners opened 9 new positions and closed 29 in Q3 2020.
  • Eversept Partners's portfolio value fell 38% quarter-over-quarter to $450M.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.